Progression-free survival was longer with tumour-specific versus standard chemotherapy in two trials, but further work is needed to improve prognosis for these patients
Findings from several studies highlight the increasing utility of this approach to identify druggable genetic alterations
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.